Enanta Pharmaceuticals Inc. is one of at least six companies working to develop a farnesoid X receptor (FXR) agonist for non-alcoholic steatohepatitis that might offer a better overall risk/benefit profile than Intercept Pharmaceuticals Inc.’s obeticholic acid (OCA) – likely to be the first drug approved for NASH – but data from its Phase IIa ARGON-1 study don’t offer a conclusive case on efficacy or tolerability.
The Boston-based infectious disease specialist unveiled data on 25 September testing 2.5mg and 1mg doses of EDP-305 in NASH patients...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)